A multicentre randomised phase II study of carboplatin in combination with gemcitabine at standard rate or fixed dose rate infusion in patients with advanced stage non-small-cell lung cancer.

Abstract

BACKGROUND Intracellular gemcitabine triphosphate (dFdCTP) levels can be optimised by administering gemcitabine at a fixed dose rate infusion. PATIENTS AND METHODS Patients with chemonaive advanced non-small cell lung cancer (NSCLC) were randomised to receive gemcitabine at a fixed dose rate gemcitabine 750 mg/m(2) over 75 min (arm A) or gemcitabine 1000… (More)

Topics

Cite this paper

@article{Soo2006AMR, title={A multicentre randomised phase II study of carboplatin in combination with gemcitabine at standard rate or fixed dose rate infusion in patients with advanced stage non-small-cell lung cancer.}, author={R A Soo and L. Z. Wang and Lai San Tham and W P Yong and M. Boyer and H. L. Lim and H. S. Lee and Michael Millward and S. Liang and Phillip Beale and S. C. Lee and Boon-cher Goh}, journal={Annals of oncology : official journal of the European Society for Medical Oncology}, year={2006}, volume={17 7}, pages={1128-33} }